Insider Trading May 28, 2026 08:19 PM

Klaviyo Co-CEO Andrew Bialecki Sells Stock Via Prearranged Trading Plan Amid Valuation Pressure

Analysis reviews the recent transactions and market context surrounding the sale of shares by a key executive at Klaviyo, Inc. (NASDAQ:KVYO).

By Leila Farooq KVYO

Andrew Bialecki, Co-Chief Executive Officer and Director of Klaviyo, Inc., executed a significant stock sale totaling approximately $3.1 million in May 2026. The transaction involved selling shares under a Rule 10b5-1 plan, occurring against a backdrop of recent financial performance and ongoing market valuation adjustments for the marketing automation company.

Klaviyo Co-CEO Andrew Bialecki Sells Stock Via Prearranged Trading Plan Amid Valuation Pressure
KVYO

Key Points

  • Andrew Bialecki executed a substantial sale of shares totaling approximately $3.1 million under a prearranged Rule 10b5-1 plan.
  • Klaviyo reported strong Q1 2026 financial results, with EPS at $0.22 and revenue reaching $358 million, beating analyst forecasts.
  • Despite robust earnings, multiple analysts, including Stifel and Piper Sandler, adjusted price targets downward citing concerns about guidance deceleration and margins.

Andrew Bialecki, who serves as Co-Chief Executive Officer, Director, and holds a ten percent ownership stake in Klaviyo, Inc. (NASDAQ:KVYO), recently completed the sale of company stock. On May 26, 2026, Mr. Bialecki sold 212,529 shares of the firm's Series A Common Stock.

The total proceeds from these transactions amounted to roughly $3,105,048. These sales were executed in compliance with a Rule 10b5-1 trading plan that Mr. Bialecki had established on May 20, 2025. The shares sold represented Series A Common Stock, and the weighted average price across these transactions was $14.61 per share, although individual transaction prices varied between $14.43 and $15.00.

Details of Share Holdings and Transactions

The stock sale followed a related acquisition where Mr. Bialecki obtained an equivalent number of Series A Common Stock shares through the conversion process involving Series B Common Stock. It is noted that each share of Klaviyo's Series B Common Stock can be converted into one share of Series A Common Stock at any time, on a one-to-one basis, without an expiration date. Following these recent movements, Mr. Bialecki directly holds 66,731,589 shares of Series B Common Stock.

Furthermore, the executive maintains indirect holdings in Series B Common Stock through various trusts and family members. These indirect holdings include:

  • The Andrew P. Bialecki Grantor Retained Annuity Trust I of 2023, holding 7,517,410 shares.
  • The Elizabeth L. Bialecki Irrevocable GST Trust of 2023, holding 517,006 shares.
  • The Andrew P. Bialecki Irrevocable GST Trust of 2023, also holding 517,006 shares.
  • Shares held by his spouse, totaling 43,218 units.

Mr. Bialecki disclaims beneficial ownership of the shares managed by these trusts, except to the extent that he has a direct pecuniary interest.


The Form 4 report detailing these transactions was formally submitted to the Securities and Exchange Commission on May 28, 2026.

Market Context and Valuation Indicators

Despite the executive sale, recent company performance and market analysis provide additional context regarding Klaviyo's valuation. The stock is currently trading at $14.74, reflecting significant downward pressure over both the past year (down 56%) and year-to-date (down 54.6%).

However, recent financial reports indicate strong operational performance. In the first quarter of 2026, Klaviyo Inc. reported impressive results that surpassed analyst expectations. Specifically, the company achieved earnings per share (EPS) of $0.22, exceeding the projected $0.20, and announced revenue totaling $358 million, which outperformed the anticipated figure of $348.6 million.

Despite these positive financial outcomes, market analysts have subsequently revised their stock price targets for Klaviyo. Stifel lowered its target from $35 to $28, although it maintained a Buy rating and cited guidance deceleration as a factor. Similarly, Piper Sandler reduced its target from $30 to $26 due to concerns regarding margins, while retaining an Overweight rating.

The company has emphasized its focus on enhancing precision and accuracy in forecasting as it continues scaling its operations. From a financial health perspective, Klaviyo maintains a solid position, boasting a current ratio of 4.23 and possessing more cash reserves than outstanding debt. An analysis provided by InvestingPro suggests that Klaviyo may appear undervalued at present levels, with shares trading near their 52-week low of $13.53.

Key Takeaways for Investors

The reported transactions and associated market data highlight several key points for industry observers: